Ipilimumab is a medication used in the management and treatment of metastatic melanoma. It is in the CTLA-4 monoclonal antibody class of drugs. This activity illustrates the indications, action, and contraindications for Ipilimumab as a valuable agent in managing metastatic melanoma and several other tumors. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with metastatic melanoma and related conditions.

**Objectives:**
- Identify the mechanism of action of ipilimumab.
- Describe the adverse effects of ipilimumab.
- Review the appropriate monitoring for ipilimumab.
- Discuss interprofessional team strategies for improving care coordination and communication to advance ipilimumab and improve outcomes.